Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare, Inc. (ALHC) reported third-quarter 2026 revenue of $1,358.290 million, up 36.7% from $993.695 million a year earlier. It recorded a net loss of $8.052 million, versus net income of $3.729 million; adjusted EBITDA was $21.808 million, down 32.8%. Membership reached 301,200 as of September 30, 2026, 31.2% above the prior-year count.
For the first nine months, revenue was $3,929.120 million, net income was $39.924 million versus $10.028 million, and adjusted EBITDA was $127.804 million, up 29.7%. The medical benefits ratio was 89.5%, compared with 87.2%. For the 2027 rating year, the California HMO plan serving approximately 75% of members received a 3.5-Star Rating; each of the six other eligible plans had a 4.0-Star or higher rating, including three at 4.5 stars.
As of September 30, 2026, cash and cash equivalents were $727.694 million, and the carrying value of long-term debt, net of issuance costs, was $324.497 million. The $200 million revolving credit facility had no outstanding debt, and the company reported compliance with all financial covenants.
Alignment Healthcare, Inc. (ALHC) reported third-quarter 2026 revenue of $1,358.3 million, up 36.7% year over year, and approximately 301,200 health plan members, up 31.2%. Adjusted gross profit was $142.2 million, up 11.6%; the company recorded a $3.8 million operating loss and an $8.1 million net loss, compared with $3.7 million net income a year earlier. Adjusted EBITDA was $21.8 million, down 32.8%, and the medical benefits ratio based on adjusted gross profit was 89.5%, up approximately 240 basis points.
Alignment raised full-year 2026 membership and revenue guidance and lowered adjusted gross profit and adjusted EBITDA guidance, citing higher medical costs experienced in the third quarter. Fourth-quarter guidance is no less than 305,000 members, $1,316 million revenue, $104 million adjusted gross profit and $(28) million adjusted EBITDA; full-year guidance is no less than 305,000 members, $5,245 million revenue, $575 million adjusted gross profit and $100 million adjusted EBITDA. The revised outlook assumes no benefit from actions underway.
Alignment Healthcare, Inc. (ALHC) expects its California HMO contract H3815 to receive a 3.5-Star Rating for 2027, down from 4.0 stars for 2026. H3815 serves approximately 75% of the company’s health plan membership. Alignment expects each of its six other eligible plans to retain a 4.0-Star rating or higher; three achieved 4.5-Star ratings.
Alignment says the 2027 ratings are not expected to affect revenue for fiscal 2026 or 2027, but the change in performance will affect quality bonus payments for fiscal 2028. It expects provider risk-sharing arrangements to offset a portion of the impact. The company attributes the H3815 decline primarily to higher industry cut points and a decline in certain triple-weighted measures across Health Outcomes Survey (HOS) and Part D. About 50% of its membership joined within the past two years, and the company expects earnings growth from existing members to support its margin trajectory.
Alignment Healthcare, Inc. (ALHC) Chief Medical Officer Hyong Kim reported a sale of 32,479 shares on October 6, 2026, at a weighted-average price of $8.30 per share. The shares were required to be sold to cover tax withholding obligations connected with RSU vesting. After the sale, Kim directly held 299,271 shares.
Alignment Healthcare, Inc. (ALHC) lists a proposed sale of 36,000 common shares by Hyong (Ken) Kim, M.D., its Chief Medical Officer, with an aggregate market value of $305,280 and an approximate sale date of October 6, 2026. The transaction is described as a sale-to-cover, not a discretionary trade; the actual number of shares sold will be determined by applicable tax withholding rates and the stock price at the time of sale. The shares were acquired through vesting of 85,034 restricted stock units on October 4, 2023, under the issuer’s 2021 Equity Incentive Plan.
Alignment Healthcare, Inc. is the issuer whose common stock BlackRock, Inc. reported beneficially owning 23,530,373 shares, or 11.3%, as of September 30, 2026. The reported amount reflects certain BlackRock business units and subsidiaries and affiliates, and excludes other business units whose beneficial ownership is disaggregated. BlackRock reported sole voting power over 23,225,544 shares and sole dispositive power over 23,530,373 shares, with no shared voting or dispositive power. Various persons may direct receipt of dividends or sale proceeds, but no one person's interest is more than 5% of the outstanding common shares.
Alignment Healthcare, Inc. (ALHC) reported that EVP, Corporate Affairs Joseph S. Konowiecki, a director and officer, sold 23,511 shares of common stock on September 17, 2026 at a weighted-average price of $8.61 per share. According to the disclosure, the sale was made to cover tax withholding obligations arising from the vesting of restricted stock units and is described as not a discretionary trade. Following this transaction, Konowiecki directly holds 1,080,305 shares of Alignment Healthcare common stock.
Alignment Healthcare, Inc. (ALHC) reported that Chief Executive Officer and director John E. Kao sold 27,400 shares of common stock on September 14, 2026 at $13.00 per share, in a sale described as a Rule 10b5-1 plan transaction and executed through an indirect holding.
The sold shares were held by the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee; following this transaction, that trust held 590,766 shares indirectly. Separately, Mr. Kao also reported a direct holding of 1,223,473 shares of Alignment Healthcare common stock as of the same date.
Alignment Healthcare, Inc. (ALHC) received a Rule 144 notice from director and EVP, Corporate Affairs Joseph Konowiecki covering a proposed sale of 26,000 shares of common stock through E-Trade, with an aggregate market value of $226,460, and an approximate sale date of September 17, 2026 on the Nasdaq Stock Market.
The shares relate to common stock acquired upon vesting of restricted stock units granted on September 14, 2023 under the company’s 2021 Equity Incentive Plan, with 43,554 shares acquired on that date. The notice states the transaction is a sale-to-cover for tax withholding and not a discretionary trade. It also lists prior three-month sales under a 10b5-1 sales plan totaling 75,000 shares for approximately $1.73 million.
Alignment Healthcare, Inc. (ALHC) reported that President Dawn Christine Maroney sold 122,707 shares of common stock on September 11, 2026. The shares were sold at a weighted-average price of $12.68 per share in multiple trades between $12.394 and $13.17 to cover tax withholding obligations arising from the vesting of restricted stock units, and the company notes this was not a discretionary trade. Following these sales, Maroney directly holds 794,606 shares of Alignment Healthcare common stock.